Sublingual semaglutide offered to UK practices despite Novo Nordisk concerns

Regulatorysublingual semaglutideNegative

AI Analysis

Summary

Sublingual semaglutide without marketing authorization is being offered to UK practices despite Novo Nordisk concerns, with claims it could minimize gastric side effects.

Importance:3/10

Sentiment:

-0.30

regulatorymarketing authorisationsublingual formulationUK marketoff-label

Related Companies

$NVO

Read the original article

Published by Pharmaceutical Technology on July 31, 2026 10:57 AM

Read Original